Axovant to Present at Two Upcoming Investor Conferences

From Startup Axovant

Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-present-two-upcoming-investor-conferences-1

BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) — Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheruvu will participate in a fireside chat at the Chardan Annual Genetic Medicines Conference 2018 on October 9, 2018 at 3:15 p.m. ET.
A live webcast will be available for each conference in the Events section of Axovant’s website at www.axovant.com. A replay will be available for 30 days following each conference.
About Axovant Sciences
Axovant is a clinical-stage neurological gene therapy company focused on developing a pipeline of clinical and nonclinical product candidates for debilitating diseases such as Parkinson’s disease, oculopharyngeal muscular dystrophy, ALS, frontotemporal dementia, and other indications. Axovant is also developing small molecules for the treatment of Lewy body dementia and other neurology and psychiatry indications. For more information, visit www.axovant.com.
Contacts:
Investors
Tricia Truehart(631) 892-7014investors@axovant.com

Source: Axovant Sciences Ltd.

Please visit their site for more information: Axovant.com

All,Biotechnology,Healthcare News,Startup News
2018-09-21 05:50:51